In CLL, as opposed to DLBCL, activation of BCR signaling does not involve activating BCR pathway mutations and can thus be viewed as antigen-dependent, resulting from BCR ligation via antigens that are present in the tumor microenvironment (43). The gene discussed is BCR; the disease is neoplasm.